Locations
San Francisco, CA, USA
industry
Artificial Intelligence (AI) · Health Care · Life Science
Size
11 - 50 employees
Stage
Series B
founded in
2024
Chai Discovery develops artificial intelligence models that predict and reprogram biochemical molecule interactions to support drug discovery and molecular design. The company offers AI-driven platforms, including foundation models for molecular structure prediction and antibody design, that allow researchers and organizations to generate and assess novel molecules based on target inputs rather than extensive empirical screening. Its technology is applied to design antibodies and other molecular candidates with desired properties to help accelerate research and therapeutic development workflows. Chai Discovery partners with scientific and pharmaceutical teams to integrate its AI tools into discovery pipelines and expand access to computational design capabilities.
Something looks off?On-site & Remote